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ABSTRACT
Background.Advanced chronic kidney disease (CKD) patients,
including those receiving dialysis, have a high prevalence of thy-
roid dysfunction. Although hypothyroidism is associated with
higher death risk in end-stage renal disease (ESRD) patients, no
studies have examined whether thyroid status in the pre-ESRD
period impacts mortality after dialysis initiation.
Methods. Among US veterans with CKD identiﬁed from the
national Veterans Affairs database that transitioned to dialysis
over the period from October 2007 to September 2011, we ex-
amined the association of pre-ESRD serum thyrotropin (TSH)
levels averaged over the 1-year pre-dialysis (‘prelude’) period
with all-cause mortality in the ﬁrst year following dialysis
initiation.
Results. Among 15 335 patients in the 1-year prelude cohort,
TSH levels >5.0 mIU/L were associated with higher mortality
in expanded case-mix Cox models (reference: TSH 0.5–5.0
mIU/L): adjusted hazard ratio (aHR) [95% conﬁdence interval
(CI) 1.20 (1.07–1.33). Similar ﬁndings were observed for TSH
>5.0 mIU/L and mortality in the 2- and 5-year cohorts: aHRs
(95% CI) 1.11 (1.02–1.21) and 1.15 (1.07–1.24), respectively.
Analyses of ﬁner gradations of TSH in the 1-year prelude cohort
demonstrated that incrementally higher levels >5.0 mIU/L
were associated with increasingly higher mortality in expanded
case-mix models (reference: TSH 0.5–3.0 mIU/L): aHRs (95%
CI) 1.18 (1.04–1.33) and 1.28 (1.03–1.59) for TSH levels >5.0–
10.0 mIU/L and >10.0 mIU/L, respectively. In the 2- and 5-
year cohorts, mortality associations persisted most strongly for
those with TSH >10.0 mIU/L, particularly after laboratory co-
variate adjustment.
Conclusions. Among new ESRD patients, there is a dose-
dependent relationship between higher pre-ESRD TSH levels
>5.0 mIU/L and post-ESRD mortality. Further studies are
needed to determine the impact of TSH reduction with thyroid
hormone supplementation in this population.
Keywords: incident ESRD, mortality, pre-ESRD prelude, thy-
roid, transition
INTRODUCTION
Thyroid dysfunction is a common yet underrecognized compli-
cation among end-stage renal disease (ESRD) patients requiring
dialysis [1–9]. Comparatively greater emphasis has been placed
upon other endocrine disorders in chronic kidney disease
(CKD), such as diabetes and secondary hyperparathyroidism.
However, multiple studies have shown that both hemodialysis
and peritoneal dialysis patients have a disproportionately
higher prevalence of hypothyroidism when compared with the
general population (11–23% versus 5%, respectively) [10–15].
Despite these data, hypothyroidism may be frequently over-
looked in dialysis patients, possibly due to overlap of its accom-
panying signs and symptoms with those of uremia (e.g. fatigue,
cold intolerance, depression, impaired cognition) [6, 7, 16].
Additionally, a majority of dialysis patients have subclinical hy-
pothyroidism, defined by elevated serum thyrotropin (TSH)
levels, ranging between 5 and 10.0 mIU/L with normal range
serum free thyroxine (FT4) levels, and have been considered by
some to be secondary to kidney dysfunction rather than pri-
mary thyroid disease that merits treatment [17].
Large population-based studies indicate that thyroid dys-
function manifests during even earlier stages of nondialysis-
dependent CKD (NDD-CKD) [16, 18–23]. Indeed, multiple ob-
servational studies have shown that there is a graded association
between the prevalence of hypothyroidism with increasingly
impaired kidney function. In a study of 14 623 participants in
VC The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. 1
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the Third National Health and Nutrition Examination Survey,
there was an incrementally higher prevalence of hypothyroid-
ism with increasing severity of kidney dysfunction: 5, 11, 20, 23
and 23% with estimated glomerular filtration rates (eGFRs) of
90, 60–89, 45–59, 30–44 and <30 mL/min/1.73 m2, respec-
tively [16]. Furthermore, in a study of 461 607 US veterans with
Stages 3–5 NDD-CKD with concomitant thyroid functional
tests and serum creatinine levels, each 10 mL/min/1.73 m2 dec-
rement in eGFR was associated with an 18% higher risk of hy-
pothyroidism (defined as a serum TSH level >5.0 mIU/L or
receipt of exogenous thyroid hormone replacement), indepen-
dent of sociodemographics and comorbidities [21].
Although early studies hypothesized that thyroid hormone
deficiency may be a physiologic adaptation among ESRD
patients [24], contemporary studies in both hemodialysis and
peritoneal patients have shown that hypothyroidism defined by
serum TSH levels measured after commencement of dialysis is
associated with higher mortality risk, even in the TSH ranges
characterized as subclinical hypothyroidism [12–15]. More re-
cently, a study strictly focused upon Stage 3 NDD-CKD patients
also found that both high-normal (3.0 mIU/L) and lower
(<0.5 mIU/L) TSH levels were associated with higher death
risk, which may also approximate short-term associations of
thyroid status with mortality [25]. However, there have not
been prior studies on whether thyroid status prior to developing
irreversible kidney failure influences long-term post-ESRD
mortality among incident ESRD patients transitioning to dialy-
sis. To address this knowledge gap, through linkage of pre-
ESRD data from the national Veterans Affairs (VA) database
with post-ESRD registries [e.g. United States Renal Data System
(USRDS)] [26], we sought to examine the relationship between
pre-ESRD thyroid status during the pre-dialysis transition pe-
riod with post-ESRD mortality among US veterans with inci-
dent ESRD.
MATERIALS AND METHODS
Source cohort
We conducted a historical cohort study with longitudinal
data from the Transition of Care in CKD (TC-CKD) study, a
retrospective cohort study examining US veterans transitioning
to renal replacement therapy over the period of 1 October 2007
through 30 September 2011 [26]. Our source population con-
sisted of 52 172 patients who were identified from the national
VA database linked to USRDS registry data. Patients were in-
cluded in this study provided that they (i) were aged 18 years
at the time of study entry, (ii) had plausible person-time follow-
up (i.e. death/censoring events did not precede the exposure
date) and (iii) underwent one or more TSH measurements dur-
ing the exposure period (Supplementary data, Figure S1).
Patients were categorized into three analytic cohorts based
on having pre-ESRD observation (‘prelude’) exposure intervals
of 1, 2 or 5 years prior to transitioning to dialysis [26]. We a pri-
ori defined the 1-year prelude period cohort as our primary co-
hort. The study was approved by the Institutional Review
Boards of the University of California Irvine Medical Center,
VA Long Beach Healthcare System and Memphis VA Medical
Center.
Exposure ascertainment
To determine the impact of pre-ESRD thyroid status upon
post-ESRD mortality, we examined serial measures of TSH av-
eraged over the prelude period. Our primary exposure was
mean TSH level averaged over the 1-year prelude period, cate-
gorized according to the TSH reference range used in the gen-
eral population: <0.5, 0.5 to <5.0 and 5.0 mIU/L
(corresponding to hyperthyroid, euthyroid and hypothyroid
TSH ranges, respectively) [13, 14, 27]. The strict classification
of subclinical thyroid disease is based on a normal range serum
FT4 concentration that was not available in sufficient numbers
of our patients. In secondary analyses, we assessed thyroid sta-
tus using finer gradations of TSH, defined according to the
usual TSH ranges for these designations as overt hyperthyroid
range (<0.1 mIU/L), subclinical hyperthyroid range (0.1 to
<0.5 mIU/L), low-normal (0.5–3.0mIU/L), high-normal (>3.0
to <5.0 mIU/L), subclinical hypothyroid range (5.0 to <10.0
mIU/L) and overt hypothyroid range TSH levels (10.0 mIU/
L) [13, 14]. In sensitivity analyses, in order to flexibly examine
TSH as a continuous predictor of mortality, we examined re-
stricted cubic splines with knots defined at the 33rd and 66th
percentiles of observed TSH values (corresponding to TSH lev-
els of 1.7 and 2.9 mIU/L, respectively). The median [interquar-
tile range (IQR)] of TSH measurements per patient averaged
over the 1-, 2- and 5-year prelude intervals were 1 (1–2), 2 (1–
3) and 3 (1–5), respectively. The minimum–maximum range of
TSH measurements per patient averaged over the 1-, 2- and 5-
year prelude intervals were 1–22, 1–26 and 1–39, respectively.
Outcome ascertainment
The outcome of interest was all-cause mortality. At-risk
time began the day after dialysis initiation. All-cause mortal-
ity data, censoring events and associated dates were obtained
from VA, Center for Medicare and Medicaid Services (CMS)
and USRDS data sources. Patients were censored for kidney
transplantation, loss to follow-up or the last date of available
follow-up data (27 December 2012), whichever occurred
first.
Sociodemographic, comorbidity, medication and
laboratory data
Data from the VA and USRDS patient and medical evidence
files were used to determine patients’ baseline sociodemographic
information (e.g. age, sex, race, ethnicity) at the time of dialysis
initiation. Data on cause of ESRD and initial dialysis modality
were obtained from USRDS sources. Information about comor-
bidities at the time of dialysis initiation was extracted from the
VA Inpatient and Outpatient Medical SAS datasets [28] and
CMS datasets using International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9) diagnostic and
procedure codes and current procedural terminology codes
[29]. Charlson Comorbidity Index (CCI) scores were estimated
using the Deyo modification for administrative datasets without
including kidney disease [30]. Body mass index data were
2 A.S. You et al.
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obtained from the VA Vital Status file. Medication data were
obtained from both CMS Part D and VA pharmacy dispensation
records [31]. TSH levels and other laboratory data except serum
creatinine were obtained from the VADecision Support System-
National Data Extracts Laboratory Results files [32]. VA
Corporate Data Warehouse LabChem data files were used to ex-
tract data about pre-dialysis serum creatinine [33]. Using serum
creatinine and demographic data, eGFR was calculated using the
CKD Epidemiology Collaboration equation [34].
Statistical analysis
We estimated the association of pre-ESRD thyroid status
with post-ESRDmortality using Cox proportional hazard mod-
els. Cox models were conducted using five hierarchical levels of
covariate adjustment:
(i) minimally adjusted: adjusted for patient’s calendar
quarter of dialysis initiation to account for secular
changes in care over time;
(ii) case-mix adjusted: adjusted for covariates in the mini-
mally adjusted model, as well as age at dialysis initia-
tion, sex, race and ethnicity;
(iii) expanded case-mix model: adjusted for covariates in the
case-mix model, as well as cause of ESRD (e.g. diabetes,
hypertension, glomerulonephritis, cystic disease, other
urologic cause, other cause, unknown/missing), CCI
score, congestive heart failure (CHF), cerebrovascular
disease (CVD), coronary artery disease (CAD), hyper-
tension and hyperlipidemia;
(iv) expanded case-mix þ laboratory adjusted model: ad-
justed for covariates in the expanded case-mix model,
as well as eGFR (i.e. proxy of residual kidney function),
serum bicarbonate; and
(v) expanded case-mix þ laboratory þ medication adjusted
model: adjusted for covariates in the expanded case-mixþ
laboratory test model, as well as use of thyroid hormone
supplementation and use of anti-thyroid medications.
We a priori defined the expanded case-mix model as our
preferred model, which included core sociodemographic meas-
ures and other confounders of the association between thyroid
status and mortality. Candidate comorbidity, laboratory (i.e.
markers of metabolic status [35], kidney function [16, 21, 23,
36] and underlying illness [4]) and medication covariates were
selected as those covariates that were hypothesized to be associ-
ated with thyroid dysfunction and mortality based on published
evidence but not thought to be on causal pathways linking thy-
roid status to death. For the 1- and 2-year prelude cohorts, co-
morbidity, laboratory and medication covariates were extracted
over a time period spanning from the start of the prelude period
to 1 year prior to commencement of the prelude period. For the
5-year prelude cohort, due to a high degree of missing labora-
tory and medication data in the 1 year prior to commencement
of the 5-year prelude period (i.e. left truncation of data), only
minimally adjusted, case-mix and expanded case-mix adjusted
models were estimated.
In the 1-year prelude cohort, there were no missing values
for age and sex; remaining covariates had <1% missing values,
except CCI and comorbidities (each <5%), eGFR (15%) and
Table 1. Baseline characteristics of 1-year prelude cohort according to thyroid status
TSH (mIU/L)
Overall <0.5 0.5–5.0 >5.0 P-value
n (%) 15 335 452 (3.0) 13 237 (86.3) 1646 (10.7) N/A
Age at dialysis initiation (mean6 SD) 69.86 11.4 70.16 11.2 69.56 11.4 71.46 11.1 <0.001
Female (%) 2 2 2 2 0.85
Black race (%) 25 28 26 14 <0.001
Hispanic ethnicity (%) 7 3 7 9 <0.001
Cause of ESRD (%) 0.12
Diabetes 47 40 47 47
Hypertension 28 31 28 29
Glomerulonephritis 5 5 5 5
Cystic disease 1 1 1 1
Other urologic cause 1 1 1 1
Other cause 11 15 11 11
Unknown/missing 6 6 6 7
Comorbidities
CCI (mean6 SD) 4.26 2.7 4.26 2.8 4.26 2.7 4.56 2.8 0.002
Congestive heart failure (%) 42 41 42 48 <0.001
Coronary artery disease (%) 59 59 59 63 0.02
Cerebrovascular disease (%) 28 32 28 32 <0.001
Hypertension (%) 96 95 96 96 0.20
Hyperlipidemia (%) 83 81 83 84 0.20
Thyroid supplement use (%) 16 26 12 43 <0.001
Anti-thyroid agents (%) <1 2 <1 <1 <0.001
Laboratory results, median (IQR)
eGFR, 1-year averaged (mL/min/1.73 m2) 26 (19–39) 27 (19–41) 26 (19–38) 27 (19–41) 0.02
Serum bicarbonate (mEq/L) 25 (22–27) 25 (23–27) 25 (22–27) 25 (23–27) 0.25
TSH, thyrotropin; ESRD, end-stage renal disease; eGFR, estimated glomerular ﬁltration rate.
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serum bicarbonate (23%). Given the higher proportion of miss-
ing laboratory covariates, further adjustment for potential con-
founders in expanded case-mix þ laboratory models were
conducted as sensitivity analyses in which missing data were
handled using multiple imputation. To explore whether receipt
of thyroid-modulating therapy may be an intermediate in the
association of thyroid status with mortality, we conducted sen-
sitivity analyses in which we incrementally added receipt versus
nonreceipt of thyroid-modulating therapy (e.g. thyroid hor-
mone supplementation, anti-thyroid medication) as potential
pathway intermediates in expanded case-mix þ laboratory þ
medicationmodels and observed for effect estimate attenuation.
We also conducted subgroup analyses of thyroid status and
mortality across clinically relevant subgroups. Proportional
hazards assumptions were confirmed by graphical analysis.
Analyses and figures were generated using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA), Stata version 13.1 (Stata
Corporation, College Station, TX, USA) and SigmaPlot Version
12.5 (Systat Software, San Jose, CA, USA).
RESULTS
Study population
Among 15 335 patients who met eligibility criteria for the 1-
year prelude cohort, 3, 86 and 11% of patients had TSH levels
<0.5 mIU/L (hyperthyroid range), 0.5–5.0 mIU/L (euthyroid
range) and >5.0 mIU/L (hypothyroid range), respectively. The
median (IQR), mean 6 SD, and minimum–maximum values
of TSH averaged over the 1-year prelude period were 2.2 (1.4–
3.4), 3.26 6.4 and 0.001–210.9 mIU/L, respectively. Compared
with patients who were euthyroid, those with TSH levels >5.0
mIU/L tended to be older; were less likely to be African-
American; were more likely to have CHF, CAD and CVD; and
were more likely to be on thyroid hormone supplementation
(Table 1). Compared with patients who were euthyroid, those
with TSH levels <0.5 mIU/L were less likely to be Hispanic;
were less likely to have diabetes as the cause of ESRD; were
more likely to have CVD; and were more likely to be on anti-
thyroid medications or thyroid hormone supplementation.
Baseline characteristics stratified according to finer gradations
of TSH are shown in Supplementary data, Table S1.
Thyroid status and mortality
In primary analyses of the 1-year prelude cohort, patients
contributed a total of 12 702 patient-years of follow-up, during
which time 2837 all-cause deaths occurred. Median (IQR) at-
risk time was 12.0 (9.9–12.0) months. In minimally adjusted,
case-mix and expanded case-mix models, we observed that pre-
ESRD TSH levels >5.0 mIU/L over the 1-year prelude period
were associated with higher mortality risk (reference: TSH 0.5–
5.0 mIU/L): adjusted HRs (aHRs) [95% confidence interval
(CI)] 1.34 (1.20–1.49), 1.25 (1.12–1.39) and 1.20 (1.07–1.33), re-
spectively (Figure 1 and Supplementary data, Table S2). These
associations persisted with incremental adjustment for labora-
tory covariates [aHR (95% CI) 1.18 (1.06–1.32)] and medica-
tions [aHR (95% CI) 1.19 (1.06–1.33)]. Across all levels of
adjustment, we did not observe an association between TSH
levels<0.5 mIU/L andmortality.
In sensitivity analyses, we also examined the thyroid status–
mortality associations in the 2- and 5-year prelude cohorts
(Figure 1 and Supplementary data, Table S2). Compared with
pre-ESRD TSH levels of 0.5–5.0 mIU/L, TSH levels >5.0
mIU/L over the 2-year prelude period were associated with
higher mortality risk inminimally adjusted, case-mix, expanded
case-mix, expanded case-mix þ laboratory and expanded case-
mix þ laboratory þ medication models. Similar to the 1-year
prelude cohort, we observed that pre-ESRD TSH levels >5.0
mIU/L over the 5-year prelude period were associated with
FIGURE 1: Association of thyroid status over the 1-year prelude period with post-ESRD all-cause mortality risk. Minimally adjusted models
adjusted for patients’ calendar quarter of dialysis initiation to account for secular changes in care over time. Case-mix models adjusted for
covariates in the minimally adjusted model, as well as age at dialysis initiation, sex, race and ethnicity. Expanded case-mix model adjusted for
covariates in the case-mix model, as well as cause of ESRD, CCI score, CHF, CVD, CAD, hypertension and hyperlipidemia.
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higher mortality risk in minimally adjusted, case-mix and ex-
panded case-mix models.
TSH gradations and mortality
In secondary analyses of finer TSH gradations, minimally
adjusted analyses showed that TSH categories >3.0–5.0, >5.0–
10.0 and >10.0 mIU/L were associated with incrementally
higher death risk (reference: TSH 0.5–3.0 mIU/L): aHRs (95%
CI) 1.10 (1.01–1.21), 1.35 (1.19–1.53) and 1.48 (1.19–1.83), re-
spectively (Supplementary data, Table S3). However, upon ad-
justment for expanded case-mix covariates (‘primary model’),
only associations of TSH levels >5.0–10.0 mIU/L and >10.0
mIU/L with higher mortality persisted: aHRs (95% CI) 1.18
(1.04–1.33) and 1.28 (1.03–1.59), respectively (Figure 2 and
Supplementary data, Table S3). In expanded case-mix-adjusted
analyses of the 2-year prelude cohort, pre-ESRD TSH levels
>5.0 mIU/L were numerically higher but did not achieve statis-
tical significance, whereas there was a statistically significant as-
sociation between TSH levels >10.0 mIU/L and mortality:
aHRs (95% CI) 1.06 (0.96–1.17) and 1.37 (1.16–1.63),
respectively.
In minimally adjusted analyses of continuous TSH exam-
ined as a restricted cubic spline, pre-ESRD TSH levels >3.0
mIU/L were monotonically associated with higher death risk
(Figure 3A). However, in models adjusted for case-mix and ex-
panded case-mix covariates, we observed a higher threshold of
5.0 mIU/L above which elevated TSH levels were associated
with higher mortality risk (Figure 3B and C).
Thyroid status and mortality across clinically relevant
subgroups
In expanded case-mix analyses, we did not detect effect
modification on the basis of age, sex, race, ethnicity, CCI score,
CHF, CVD, CAD, hypertension, hyperlipidemia, thyroid
hormone supplement use or anti-thyroid medication use status:
P-interaction¼ 0.54, 0.99, 0.52, 0.74, 0.79, 0.58, 0.91, 0.72, 0.45,
0.75, 0.33 and 0.50, respectively (Figure 4 and Supplementary
data, Table S4). In all subgroups, the nominal HRs for TSH lev-
els>5.0 mIU/L were>1 except among non-White patients and
those without hypertension; nominal associations were statisti-
cally significant in the following subgroups: age 65 years,
male, White, Non-Hispanic, CCI score 5, CHF present, CHF
absent, CVD absent, CAD present, hypertension present, hy-
perlipidemia present, thyroid hormone supplement use, thyroid
hormone supplement nonuse and anti-thyroid medication
nonuse.
DISCUSSION
In a large national incident ESRD cohort of US veterans, we ob-
served that approximately 11% of patients had TSH levels in
the hypothyroid range (TSH>5.0 mIU/L) in the year preceding
transition to dialysis. After accounting for confounders of socio-
demographic and comorbidity status, we found that pre-ESRD
TSH levels exceeding 5.0 mIU/L were incrementally associated
with higher death risk in analyses examining TSH as both a cat-
egorical and continuous variable.
There is increasing recognition that aberrancies in thyroid
status, particularly hypothyroidism, are associated with height-
ened death risk in the kidney disease population [6, 7, 12–15].
The first study of dialysis patients to examine thyroid status de-
fined by serum TSH levels and mortality showed that, among a
cohort of 2715 incident/prevalent dialysis from two tertiary
care centers in Boston, hypothyroid range TSH levels (i.e. ex-
ceeding the assay reference ranges of >5.0 or >5.4 mIU/L)
ascertained at baseline were independently associated with a
35% higher death risk versus euthyroidism [12]. Although a
secondary analysis of 1000 incident/prevalent diabetic hemodi-
alysis patients from the Deutsche Diabetes Dialyse Studie (4D)
FIGURE 2: Association of TSH gradations over the 1-year prelude period with post-ESRD all-cause mortality risk. Analyses adjusted for ex-
panded case-mix covariates, which included patients’ calendar quarter of dialysis initiation, age at dialysis initiation, sex, race, ethnicity, cause
of ESRD, CCI score, CHF, CVD, CAD, hypertension and hyperlipidemia.
Pre-ESRD TSH and post-ESRD mortality 5
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study did not observe that subclinical hypothyroidism exam-
ined alone nor in conjunction with overt disease was associated
with higher mortality risk [37], subsequent studies have shown
robust hypothyroidism–mortality associations. In an analysis of
8840 national incident hemodialysis patients from a large dialy-
sis organization, hypothyroid-range TSH levels (>5.0 mIU/L)
that were measured at dialysis initiation (i.e. baseline TSH levels
as a proxy of long-term exposure–mortality associations) and
over the study period (i.e. time-dependent TSH levels as proxy
of short-term exposure–mortality associations) were indepen-
dently associated with a 47 and 62% higher death risk, respec-
tively, when compared with euthyroid range levels [13]. These
findings were corroborated in a national study of 1484 incident/
prevalent peritoneal dialysis patients among whom baseline
and time-dependent TSH levels in the hypothyroid range (>5.0
mIU/L) were also associated with lower survival [14]. Similarly,
in a prospective multicenter study of hemodialysis patients who
underwent protocolized TSH measurement every 6 months,
there was a 2.5-fold higher death risk observed with time-
dependent TSH levels in the highest versus lowest tertiles [15].
More recently, in a study of 227 422 US veterans with Stage 3
CKD, it was observed that both high-normal (3.0 mIU/L) and
lower (<0.5 mIU/L) TSH levels were associated with higher
death risk, which may also approximate short-term associations
of thyroid status with mortality [25]. Although the aforemen-
tioned studies have examined thyroid dysfunction and mortal-
ity in NDD-CKD patients who have not yet transitioned to
ESRD, as well as studies in those with pre-existing ESRD that
reflects short-term associations of thyroid status and mortality,
there has been a paucity of data regarding the long-term se-
quelae of thyroid dysfunction among NDD-CKD patients who
survive to ESRD.
To our knowledge, this is the first study that has examined
the long-term impact of thyroid status during later stages of
NDD-CKD upon the post-dialysis mortality risk of incident
ESRD patients. We observed that hypothyroid-range TSH
levels (>5.0 mIU/L) measured 1 year prior to dialysis
initiation were associated with higher death risk across
multiple secondary and sensitivity analyses. Several potential
pathways have been suggested as underlying mechanisms of the
A
C
B
FIGURE 3: Association of continuous TSH levels over the 1-year prelude period with post-ESRD all-cause mortality risk using restricted cubic
splines. Minimally adjusted models adjusted for patients’ calendar quarter of dialysis initiation to account for secular changes in care over
(Panel A). Case-mix models adjusted for covariates in the minimally adjusted model, as well as age at dialysis initiation, sex, race and ethnicity
(Panel B). Expanded case-mix models adjusted for covariates in the case-mix models, as well as cause of ESRD, CCI score, CHF, CVD, CAD,
hypertension and hyperlipidemia (Part C). Solid black lines present hazard ratios (dashed lines indicate 95% CIs) for TSH analyzed as a spline
with knots at the 33rd and 66th percentiles of observed values (1.7 and 2.9, respectively). A histogram of observed TSH values and a hazard ref-
erence ratio of 1 (solid gray line) is overlaid. TSH levels >10 mIU/L were truncated (i.e. replaced by the value of 10 mIU/L) for the purposes of
the spline analyses.
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hypothyroidism–mortality association in dialysis patients. In
the general population, hypothyroidism has been associated
with adverse cardiovascular sequelae, including systolic and di-
astolic dysfunction due to genomic and nongenomic effects of
thyroid hormone [38–40]; endothelial dysfunction and in-
creased systemic vascular resistance that in conjunction with
dyslipidemia may lead to accelerated atherosclerosis [38–41];
and changes in cardiac ion channel expression and prolonga-
tion of the QT interval, heightening the risk of malignant
arrhythmias and sudden cardiac death [40]. As both hypothy-
roidism and cardiovascular disease are common in NDD-CKD
patients, it is plausible that aberrant thyroid status during the
pre-ESRD prelude period may have long-term implications
upon cardiovascular outcomes in ESRD patients. Indeed, there
is growing evidence that thyroid hormone deficiency is associ-
ated with cardiovascular complications (e.g. endothelial
dysfunction, coronary calcification) in the dialysis population
[2–4]. Emerging data also suggest that hypothyroidism may ad-
versely impact dialysis patients via noncardiovascular pathways.
In a prospective study of 450 hemodialysis patients across 17
outpatient dialysis centers, higher TSH levels were associated
with worse physical function and energy/fatigue scores over
time as ascertained by serial Short Form 36 surveys [42]. As thy-
roid hormones have direct action in skeletal muscle [43], the
impact of hypothyroidism on impaired physical function may
be an under-recognized yet important pathway to death in this
population [42].
Another noteworthy finding in our study was the persistence
of hypothyroid-range TSH level–mortality associations after
adjustment for thyroid hormone-modulating therapy treatment
versus nontreatment status. Examination of baseline character-
istics of this cohort revealed that, among patients with
FIGURE 4: Subgroup analyses of the association of thyroid status over the 1-year prelude period with post-ESRD 1-year all-cause mortality.
Analyses adjusted for expanded case-mix covariates, which included patients’ calendar quarter of dialysis initiation, age at dialysis initiation,
sex, race, ethnicity, cause of ESRD, CCI score, CHF, CVD, CAD, hypertension and hyperlipidemia. †Lower bound of 95% CI exceeds ﬁgure
limits. HTN: hypertension; HLD: hyperlipidemia.
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hypothyroid-range TSH levels in the 1-year pre-ESRD period,
43% were prescribed thyroid hormone supplementation, who
may be representative of those with undertreated hypothyroid-
ism. Although USRDS registry data have shown that levothyr-
oxine is among the most commonly prescribed medications in
NDD-CKD and ESRD patients who are Medicare Part D
enrollees [44], it has yet to be determined whether thyroid hor-
mone supplementation effectively corrects thyroid dysfunction
in this population. In the general population, thyroid hormone
supplementation in hypothyroid patients has been shown to re-
verse adverse cardiovascular surrogates (e.g. ventricular func-
tion, endothelial dysfunction, atherosclerosis [45–47]) and to
improve certain aspects of physical function in the general pop-
ulation (e.g. strength, cardiopulmonary exercise performance
[48]). Although data examining thyroid hormone supplementa-
tion use and outcomes in the kidney disease population are
sparse, in a recent analysis of US veterans with Stage 3 CKD, it
was shown that those with untreated and undertreated hypo-
thyroidism had higher mortality risk compared with those who
were spontaneously euthyroid, whereas those who were hypo-
thyroid-treated-to-target had similar to slightly better survival
[25]. In the present study, we were neither able to determine the
indications for treatment versus nontreatment, intended TSH
target, nor direct response to therapy across individual patients.
However, our findings suggest that biochemical hypothyroid-
ism is associated with worse survival irrespective of treatment
status. At this time, prospective studies are needed to precisely
determine whether correction of hypothyroidism with thyroid
hormone supplementation improves cardiovascular endpoints,
physical function andmortality in dialysis patients.
The strengths of our study include its examination of a large
cohort of incident ESRD patients with both pre-ESRD and
post-ESRD data; comprehensive availability of information on
comorbidities, laboratory tests, medications and clinical events;
and reduced confounding on the basis of differential healthcare
access and nonuniform medical care by receiving care within
the VA healthcare system. However, several limitations of our
study bear mention. First, the indications for TSH testing in
this cohort, a requirement for inclusion in the study, are un-
known. However, this inclusion criterion was required of all
patients irrespective of underlying thyroid status and thus
should not impair the study’s internal validity. Second, we de-
fined thyroid status using serum TSH only, as the most sensi-
tive and specific single metric of thyroid function in the general
population, given its inverse logarithmic association with se-
rum triiodothyronine (T3) and T4 levels, and its robust charac-
teristics in the setting of nonthyroidal illness and uremia [6, 7,
27]. In contrast, the FT4 assay, used to classify subclinical ver-
sus overt functional thyroid disease, is an analog assay and de-
pendent on normal hormone protein binding and may provide
spurious results in conditions where serum protein levels are
low (e.g. malnutrition) or circulating substances impair hor-
mone protein binding (e.g. uremia) [6, 7, 49]. In addition, the
vast majority of circulating T3 is derived from the peripheral
conversion of T4-to-T3, which is highly sensitive to inflamma-
tion, malnutrition and mild illness independent of thyroid
functional status [6, 7, 50]. Third, our examination of pre-
ESRD TSH levels and post-ESRDmortality neither assesses the
relationship between thyroid status and short-term death risk,
nor did our analyses include those who maintained stable kid-
ney function, experienced death or underwent kidney trans-
plantation prior to dialysis initiation, or those who declined
dialysis. However, as prior data have confirmed an association
between thyroid status and short-term mortality risk in dialysis
patients [13–15], our intention was to specifically examine the
long-term impact of thyroid aberrancies in the pre-ESRD pe-
riod upon post-ESRD mortality. Fourth, as the study cohort
was predominantly male, our findings may have limited gener-
alizability to populations with differing sociodemographic
composition. Lastly, as with all observational studies, residual
confounding cannot be excluded, and our findings do not con-
firm a causal association between thyroid status and mortality
risk.
In summary, our study shows that incident ESRD patients
with TSH levels in the hypothyroid range during the pre-ESRD
prelude period have higher post-ESRD mortality, and this risk
is increasingly stronger with incrementally higher TSH levels.
At this time, future studies are needed to precisely define the
underlying mechanistic pathways linking hypothyroidism with
mortality. There is a disproportionately high prevalence of ab-
normally elevated serum TSH levels and hypothyroidism in di-
alysis patients, and a growing body of evidence demonstrating
its adverse associations with survival. Rigorous studies, includ-
ing randomized clinical trials, are needed to determine the im-
pact of longitudinal thyroid hormone treatment on mortality
and other clinically relevant endpoints (i.e. cardiovascular and
patient-centered outcomes) in this population.
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